Circulating levels of soluble apoptosis-related molecules in patients with multiple sclerosis

Journal of Neuroimmunology

Volumn 263, Issue 1-2, 2013, Pages 152-154

  Moreno, Montserrat ^a   Sáenz Cuesta, Matías ^a   Castilló, Joaquín ^a   Cantó, Ester ^a   Negrotto, Laura ^a   Vidal Jordana, Angela ^a   Montalban, Xavier ^a   Comabella, Manuel ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Apoptosis; Fas; FasL; Multiple sclerosis; Relapse; TRAIL

Indexed keywords

FAS ANTIGEN; FAS LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE CLASSIFICATION; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; RELAPSE; REMISSION;

APOPTOSIS; FAS; FASL; MULTIPLE SCLEROSIS; RELAPSE; TRAIL;

ADULT; ANTIGENS, CD95; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BIOLOGICAL MARKERS; DOWN-REGULATION; FAS LIGAND PROTEIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; SOLUBILITY; TNF-RELATED APOPTOSIS-INDUCING LIGAND; YOUNG ADULT;

EID: 84884813763     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.07.013     Document Type: Article

References (22)

1. Aktas O., Prozorovski T., Zipp F. Death ligands and autoimmune demyelination. Neuroscientist 2006, 12:305-316.
2. Aktas O., Schulze-Topphoff U., Zipp F. The role of TRAIL/TRAIL receptors in central nervous system pathology. Front. Biosci. 2007, 12:2912-2921.
3. Boylan M.T., Crockard A.D., McDonnell G.V., McMillan S.A., Hawkins S.A. Serum and cerebrospinal fluid soluble Fas levels in clinical subgroups of multiple sclerosis. Immunol. Lett. 2001, 78:183-187.
4. Cheng J., Zhou T., Liu C., Shapiro J.P., Brauer M.J., Kiefer M.C., Barr P.J., Mountz J.D. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994, 263:1759-1762.
5. Ciusani E., Frigerio S., Gelati M., Corsini E., Dufour A., Nespolo A., La M.L., Milanese C., Massa G., Salmaggi A. Soluble Fas (Apo-1) levels in cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol. 1998, 82:5-12.
6. Comi C., Leone M., Bonissoni S., DeFranco S., Bottarel F., Mezzatesta C., Chiocchetti A., Perla F., Monaco F., Dianzani U. Defective T cell fas function in patients with multiple sclerosis. Neurology 2000, 55:921-927.
7. Falschlehner C., Schaefer U., Walczak H. Following TRAIL's path in the immune system. Immunology 2009, 127:145-154.
8. Hagman S., Raunio M., Rossi M., Dastidar P., Elovaara I. Disease-associated inflammatory biomarker profiles in blood in different subtypes of multiple sclerosis: prospective clinical and MRI follow-up study. J. Neuroimmunol. 2011, 234:141-147.
9. Hebb A.L., Moore C.S., Bhan V., Robertson G.S. Effects of IFN-B on TRAIL and decoy receptor expression in different immune cell populations from MS patients with distinct disease subtypes. Autoimmun. Dis. 2010, 2011:485752.
10. Kurne A., Guc D., Canpinar H., Aydin O.F., Sayat G., Yorubulut M., Esendagli G., Karabudak R. Analysis of BAFF and TRAIL expression levels in multiple sclerosis patients: evaluation of expression under immunomodulatory therapy. Acta Neurol. Scand. 2011, 123:8-12.
11. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
12. Mahovic D., Petravic D., Petelin Z., Zurak N., Horvat G., Hajnsek S. Level of sFas/APO 1 in serum and cerebrospinal fluid in multiple sclerosis. Clin. Neurol. Neurosurg. 2004, 106:230-232.
13. Pender M.P. Treating autoimmune demyelination by augmenting lymphocyte apoptosis in the central nervous system. J. Neuroimmunol. 2007, 191:26-38.
14. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., Tourtellotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 1983, 13:227-231.
15. Rinta S., Kuusisto Hanna, Raunio M., Paalavuo R., Levula M., Lehtimäki T., Elovaara I. Apoptosis-related molecules in blood in multiple sclerosis. J. Neuroimmunol. 2008, 205:135-141.
16. Schneider P., Holler N., Bodmer J.L., Hahne M., Frei K., Fontana A., Tschopp J. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 1998, 187:1205-1213.
17. Sellner J., Greeve I., Findling O., Grandgirard D., Leib S.L., Mattle H.P. Atorvastatin does not alter serum levels of sCD95 and sCD95L in multiple sclerosis. Clin. Exp. Immunol. 2008, 152:280-284.
18. Suda T., Hashimoto H., Tanaka M., Ochi T., Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J. Exp. Med. 1997, 186:2045-2050.
19. Todaro M., Zeuner A., Stassi G. Role of apoptosis in autoimmunity. J. Clin. Immunol. 2004, 24:1-11.
20. Wandinger K.P., Lünemann J.D., Wengert O., Bellmann-Strobl J., Aktas O., Weber A., Grundström E., Ehrlich S., Wernecke K.D., Volk H.D., Zipp F. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 2003, 361:2036-2043.
21. Zipp F. Apoptosis in multiple sclerosis. Cell Tissue Res. 2000, 301:163-171.
22. Zipp F., Weller M., Calabresi P.A., Frank J.A., Bash C.N., Dichgans J., McFarland H.F., Martin R. Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis. Ann. Neurol. 1998, 43:116-120.